



Novel Perspectives on Hypoxia in Cancer

Guest Editor:

Prof. Dr. Mark W Dewhirst
Duke Cancer Institute, Duke
University, Durham, NC, USA

Deadline for manuscript
submissions:
closed (31 July 2021)


Message from the Guest Editor

Dear Colleagues,

Hypoxia is a complex and ubiquitous feature of nearly all solid cancers that increases the transcriptional activity of the hypoxia-inducible transcription factor HIF-1 which plays a broad role in many features of tumorigenesis, contributing to angiogenesis, alterations in tumor microenvironment, tumor progression and metastasis. Hypoxia negatively influences nearly every form of cancer therapy, including radiotherapy, chemotherapy and immunotherapy. Despite its overall prominence in cancer biology, no standard of care has been established to reduce the impact of hypoxia. This Special Issue of *Cancers* will provide a comprehensive overview of these subjects, with a focus on the development of novel approaches to reduce the impact of hypoxia in human cancers.

Prof. Mark W Dewhirst
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)